Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
Pedro Mezquita RayaFrancisco Javier Ampudia BlascoBarnaby HuntVirginia MartinBrian Larsen ThorstedAmaury BasseHermione C PricePublished in: Diabetes, obesity & metabolism (2019)
Long-term projections based on real-world evidence indicated that IDegLira is likely to improve clinical outcomes and reduce costs or be cost-effective compared with other injectable regimens in people with type 2 diabetes in Spain.